Pharmaceutical Companies

The shift also comes as pharmaceutical companies invest in newer technologies that could change how influenza vaccines are developed and manufactured.

Axogen expects to complete the transaction in the fourth quarter of 2026, adding BioCircuit’s NerveTape to its portfolio.

The facility will add to ABEC’s existing manufacturing operations in Bethlehem, Pennsylvania, and Springfield, Missouri, as well as its facilities in Fermoy and Kells, Ireland.

It will house about 325 employees, including 260 laboratory scientists, and provide adaptable laboratories, collaborative workspaces and shared technology platforms.

Solstice Oncology plans to begin enrolment in a Phase II clinical trial of porustobart in combination with pembrolizumab in the fourth quarter of 2026.

Encoded plans to use the proceeds primarily to fund a pivotal trial of ETX101 in infants and young children with SCN1A positive Dravet syndrome.

The rollout follows the drug’s approval in China in June 2026 and marks the start of its wider clinical use for people requiring urgent post-exposure protection against rabies.

Novartis India’s board approved the transaction before the company signed an asset purchase agreement and trademark assignment deeds with Pfizer and Pfizer Products.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurring symptoms, with the CIC report indicating that China had more than 54 million people living with AD in 2024.

The share repurchase programme will be funded primarily through proceeds from the sale of an approximately 6% stake in Gland Pharma for about US$294 million.